[HTML][HTML] Identification of a synergistic multi-drug combination active in cancer cells via the prevention of spindle pole clustering
A Weiss, M Le Roux-Bourdieu, M Zoetemelk… - Cancers, 2019 - mdpi.com
A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity.
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
[HTML][HTML] Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
A Weiss, M Le Roux-Bourdieu, M Zoetemelk… - Cancers, 2019 - ncbi.nlm.nih.gov
A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity.
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
A Weiss, M Le Roux-Bourdieu, M Zoetemelk… - …, 2019 - search.proquest.com
A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity.
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
A Weiss, M Le Roux-Bourdieu, M Zoetemelk… - …, 2019 - pubmed.ncbi.nlm.nih.gov
A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity.
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering.
A Weiss, M Zoetemelk, GM Ramzy, M Rausch, D Harry… - Cancers, 2019 - europepmc.org
A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity.
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering.
A Weiss, M Zoetemelk, GM Ramzy, M Rausch, D Harry… - Cancers, 2019 - folia.unifr.ch
English A major limitation of clinically used cancer drugs is the lack of specificity resulting in
toxicity. To address this, we performed a phenotypically-driven screen to identify optimal …
toxicity. To address this, we performed a phenotypically-driven screen to identify optimal …
Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering.
A Weiss, M Zoetemelk, GM Ramzy, M Rausch, D Harry… - Cancers, 2019 - sonar.ch
English A major limitation of clinically used cancer drugs is the lack of specificity resulting in
toxicity. To address this, we performed a phenotypically-driven screen to identify optimal …
toxicity. To address this, we performed a phenotypically-driven screen to identify optimal …
[PDF][PDF] Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
A Weiss, M Le Roux-Bourdieu, M Zoetemelk… - pdfs.semanticscholar.org
A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity.
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
[PDF][PDF] Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
A Weiss, M Le Roux-Bourdieu, M Zoetemelk… - access.archive-ouverte.unige.ch
A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity.
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
[PDF][PDF] Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
A Weiss, M Le Roux-Bourdieu, M Zoetemelk… - scienceopen.com
A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity.
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …
To address this, we performed a phenotypically-driven screen to identify optimal multidrug …